Skip to main content
SpringerLink
Log in

Bone marrow transplantation for Hodgkin’s disease, non-Hodgkin’s lymphoma and multiple myeloma

  • Chapter
Bone Marrow Transplantation

Part of the book series: Cancer Treatment and Research ((CTAR,volume 50))

  • 87 Accesses

Abstract

In the last 20 years many chemotherapeutic agents as well as radiation therapy have demonstrated a steep dose-response curve for many malignancies [1]. Unfortunately, toxicity also increases with dose escalation. In order to circumvent the hematologic toxicity, or to replace a diseased marrow, strategies have been developed to reconstitute the bone marrow and to allow the delivery of high-dose chemotherapy and/or radiotherapy with curative intent. The hematopoietic stem cell was identified in 1961 by Till and McCullough as the cell capable of self-renewal and differentiation into the four main hematopoietic cell lines that allow for marrow reconstitution [2].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Skipper HE, Schabel FM Jr, Mellet LB, et al. Implications of biochemical, cytokinetic, pharmacologic and toxicological relationships in the design of the optimal therapeutic schedules. Cancer Chemother Rep 1970; 54:431–436.

    PubMed  CAS  Google Scholar 

  2. Till JE, McCulloch EA. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat Res 1961; 14:213–216.

    Article  PubMed  CAS  Google Scholar 

  3. Advisory Committee for the International Autologous Bone Marrow Transplantation Registry. Bone marrow autotransplantation in man: Report of an international cooperative study. Lancet 1986; 2:960–962.

    Google Scholar 

  4. Mauch P, Lewin A, Hellman S. The role of radiation therapy in the treatment of stage I and II Hodgkin’s disease. In: Malignant Lymphomas, Rosenberg SA, Kaplan HS, eds. Academic Press, New York, 1982; 452–467.

    Google Scholar 

  5. Canellos GP, Young RC, DeVita VT. Combination chemotherapy for advanced Hodgkin’s disease in relapse following extensive radiotherapy. Clin Pharmacol Ther 1972; 13:750–754.

    Google Scholar 

  6. DeVita VT Jr, Simon RM, Hubbard SM, et al. Curability of advanced Hodgkin’s disease with chemotherapy: Long-term follow up of MOPP treated patients at NCI. Ann Intern Med 1980; 92:587–595.

    PubMed  Google Scholar 

  7. DeVita VT, Serpick A. Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Proc Am Assoc Cancer Res 1967; 8:13.

    Google Scholar 

  8. Sutcliffe SB, Wrigley PF, Peto J. MVPP chemotherapy regiment for advanced Hodgkin’s disease. Br Med J 1978; 1:679–685.

    Article  PubMed  CAS  Google Scholar 

  9. Vose JM, Armitage JO, Weisenburger DD: ChlVPP — an effective and well tolerated alternative to MOPP therapy for Hodgkin’s disease. Am J Clin Oncol 1988; 11:423–426.

    Article  PubMed  CAS  Google Scholar 

  10. Santoro A, Bonfante V, Bonadonna G, et al. Salvage chemotherapy with ABVD in MOPP resistant Hodgkin’s disease. Ann Intern Med 1982; 96:139–143.

    PubMed  CAS  Google Scholar 

  11. Sutcliffe SB, Wrigley PF, Stansfeld AG, et al. Adriamycin, bleomycin, vinblastine and imidazole carbamide (ABVD) therapy for advanced Hodgkin’s disease resistant to mustine, vinblastine, procarbazine and prednisone (MVPP). Cancer Chemother Pharmacol 1979; 2:209–213.

    Article  PubMed  CAS  Google Scholar 

  12. Harker WG, Kushlan P, Rosenberg SA, et al. Combination chemotherapy for advanced Hodgkin’s disease after failure of MOPP: ABVD and B-CAVe. Ann Intern Med 1984; 101:440–446.

    PubMed  CAS  Google Scholar 

  13. Fisher RI, DeVita VT, Hubbard SP, et al. Prolonged disease-free survival in Hodgkin’s disease with MOPP reinduction after first relapse. Ann Intern Med 1979; 90:761–763.

    PubMed  CAS  Google Scholar 

  14. Appelbaum FR, Sullivan KM, Thomas ED, et al. Allogeneic marrow transplantation in the treatment of MOPP-resistant Hodgkin’s disease. J Clin Oncol 1985; 3:1490–1494.

    PubMed  CAS  Google Scholar 

  15. Appelbaum FR, Sullivan KM, Buckner CD, et al. Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation and marrow transplantation. J Clin Oncol 1987;5:1340–1347.

    PubMed  CAS  Google Scholar 

  16. Bierman PJ, Jagannath S, Dicke KA, et al. High dose cyclophosphamide, carmustine, and etoposide (CBV) in 128 patients with Hodgkin’s disease. Blood 1988; 72(Suppl l):238a.

    Google Scholar 

  17. Jagannath S, Dicke KA, Armitage JO, et al. High-dose cyclophosphamide, carmustine and etoposide and autologous bone marrow transplantation for relapsed Hodgkin’s disease. Ann Intern Med 1986; 104:163–168.

    PubMed  CAS  Google Scholar 

  18. Carella AM, Santini G, Giodano A, et al. High-dose chemotherapy and non-frozen autologous bone marrow transplantation in relapsed advanced lymphomas or those resistant to conventional chemotherapy. Cancer 1984; 54:2836–2839.

    Article  PubMed  CAS  Google Scholar 

  19. Carella AM, Congiu AM, Santini G, et al. Autologous bone marrow transplantation in the treatment of 25 advanced Hodgkin’s disease patients. J Clin Oncol, in press.

    Google Scholar 

  20. Philip T, Dumont J, Teillet F, et al. High dose chemotherapy and autologous bone marrow transplantation in refractory Hodgkin’s disease. Br J Cancer 1986; 53:737–742.

    Article  PubMed  CAS  Google Scholar 

  21. Wolff SN, Phillips GL, Fay JW, et al. Treatment of advanced Hodgkin’s with intensive chemo-radiotherapy and autologous bone marrow transplantation. In; Third International Conference on Autologous Bone Marrow Transplantation, K Dicke, ed, 1987.

    Google Scholar 

  22. Jagannath S, Armitage JO, Spitzer G, et al. Prognostic factors predicting for response to high dose chemotherapy and authologous bone marrow transplantation (ABMT) for relapsed Hodgkin’s disease. Blood 1986; 68:274a.

    Google Scholar 

  23. Phillips GL, Reece PE. Clinical studies of autologous bone marrow transplantation in Hodgkin’s disease. Clin Haematol 1986; 15:155–166.

    Google Scholar 

  24. Anderson CC, Goldstone AH, Souhami RL, et al. Very high dose chemotherapy with autologous bone marrow rescue in adult patients with resistant relapsed lymphoma. Cancer Chemother Pharmacol 1986; 16:170–175.

    Article  PubMed  CAS  Google Scholar 

  25. Sullivan KM, Appelbaum FR, Horning SJ, et al. Selection of patients with Hodgkin’s disease and non-Hodgkin’s lymphoma for bone marrow transplantation. Int J Cell Cloning 1986; 4(Suppl 1):94–106.

    Article  PubMed  Google Scholar 

  26. Benjamin D, Magrath IT, Douglass EC, et al. Derivation of lymphoma cell lines form microscopically normal bone marrow in patients with undifferentiated lymphoma: Evidence of occult bone marrow involvement. Blood 1983; 61:1017–1019.

    PubMed  CAS  Google Scholar 

  27. Kessinger A, Armitage JO, Landmark KJD. Reconstitution of human hematopoietic function with autologous cryopreserved circulating stem cells. Exp Hematol 1986; 14:192–196.

    PubMed  CAS  Google Scholar 

  28. Kessinger A, Armitage JO. High dose therapy with autologous peripheral stem cell transplantation for patients with lymphoma metastatic to bone marrow. Proc Am Soc Clin Oncol 1988; 7:860.

    Google Scholar 

  29. Nemunaitis J, Singer JW, Buckner CD. Use of stimulating factor in autologous bone marrow transplantation for lymphoid malignancies. Blood 1988; 72:834–836.

    PubMed  CAS  Google Scholar 

  30. The Non-Hodgkin’s Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classification of non-Hodgkin’s lymphomas; Summary and description of a Working Formulation for clinical usage. Cancer 1982; 49:2112–2135.

    Article  Google Scholar 

  31. Portlock CS: ‘Good-risk’ non-Hodgkin’s lymphomas: Approaches to management. Semin Hematol 1983; 20:25–34.

    PubMed  CAS  Google Scholar 

  32. Horwich A, Peckham M: ‘Bad-risk’ and non-Hodgkin’s lymphomas. Semin Hematol 1983; 20:35–38.

    PubMed  CAS  Google Scholar 

  33. McKelvey EM, Gottlieb JA, Wilson HE, et al. Hydroxyl-daunomycin (adriamycin) containing chemotherapy in malignant lymphoma. Cancer 1976; 38:1484–1493.

    Article  PubMed  CAS  Google Scholar 

  34. Skarin AT, Canellos GP, Rosenthal DS, et al. Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD). J Clin Oncol 1983; 1:91–98.

    PubMed  CAS  Google Scholar 

  35. Connors JM, Klimo P. Updated clinical experience with MACOP-B. Semin Hematol 1987; 24:25–34.

    Google Scholar 

  36. Cabanillas F, Hagemeister FB, Bodey GP, et al. IMVP-16: An effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood 1982; 60:693–697.

    PubMed  CAS  Google Scholar 

  37. Tseng A, Jacobs, C, Coleman CN, et al. Treatment of refractory non-Hodgkin’s lymphomas of unfavorable histology with teniposide, cytarabine, and cisplatin. Cancer Treat Rep 1987; 71:659–660.

    PubMed  Google Scholar 

  38. Fefer A, Einstein AB, Thomas ED, et al. Bone marrow transplantation for hematologic neoplasia in 16 patients with identical twins. N Engl J Med 1974; 290:1389–1393.

    Article  PubMed  CAS  Google Scholar 

  39. Appelbaum FR, Fefer A, Cheever MA, et al. Treatment of non-Hodgkin’s lymphoma with marrow transplantation in identical twins. Blood 1981; 58:509–513.

    PubMed  CAS  Google Scholar 

  40. Appelbaum FR, Sullivan KM, Thomas ED, et al. Marrow transplantation as treatment for patients with recurrent malignant lymphoma. Int J Cell Cloning 1985; 3:216–217.

    Google Scholar 

  41. Appelbaum FR, Thomas ED, Buckner CD, et al. Treatment of non-Hodgkin’s lymphoma with chemoradiotherapy and allogeneic marrow transplantation. Hematol Oncol 1983; 1:149–157.

    Article  PubMed  CAS  Google Scholar 

  42. O’Leary M, Ramsay NKC, Nesbit ME, et al. Bone marrow transplantation for non-Hodgkin’s lymphoma in children and young adults. Am J Med 1983; 74:497–501.

    Article  PubMed  Google Scholar 

  43. Phillips GL, Herzig RH, Lazarus HM, et al. High-dose chemotherapy, fractionated TBI and allogeneic marrow transplantation for malignant lymphoma. J Clin Oncl 1986; 4:480–488.

    CAS  Google Scholar 

  44. Ernst P, Maraninivtri D, Jacobsen N, et al. Marrow transplantation for non-Hodgkin’s lymphoma: A multi-centre study from the European Co-operative Bone Marrow Transplant Group. Bone Marrow Transplantation 1986; 1:81–86.

    PubMed  CAS  Google Scholar 

  45. Nademanee AP, Forman SJ, Schmidt GM, et al. Allogeneic bone marrow transplantation for high risk non-Hodgkin’s lymphoma during first complete remission. Blut 1987; 55:11–18.

    Article  PubMed  CAS  Google Scholar 

  46. Appelbaum FR, Herzig GP, Ziegler JC, et al. Successful engraftment of cryopreserved autologous bone marrow in patients with malignant lymphoma. Blood 1978; 52:85–95.

    PubMed  CAS  Google Scholar 

  47. Phillips GL, Herzig RH, Lazarus HM, et al. Treatment of resistant malignant lymphoma with cyclophosphamide, total body irradiation, and transplantation of cyropreserved autologous bone marrow. N Engl J Med 1984; 310:1557–1561.

    Article  PubMed  CAS  Google Scholar 

  48. Armitage JO, Jagannath S, Spitzer G, et al. High-dose therapy and autologous bone marrow transplantation as salvage therapy for patients with diffuse large cell lymphoma. Eur J Cancer Clin Oncol 1986; 22:871–877.

    Article  PubMed  CAS  Google Scholar 

  49. Philip T, Armitago JO, Spitzer G, et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate grade or high-grade non-Hodgkin’s lymphoma. N Engl J Med 1987; 316:1493–1498.

    Article  PubMed  CAS  Google Scholar 

  50. Gulati SC, Shank B, Black P, et al. Autologous bone marrow transplantation for patients with poor prognosis lymphoma. J Clin Oncol 1988; 6:1303–1313.

    PubMed  CAS  Google Scholar 

  51. Philip T, Hartman O, Biron P, et al. High-dose therapy and authologous bone marrow transplantation in partial remission after first line induction therapy for diffuse non-Hodgkin’s lymphoma. J Clin Oncol 1988; 6:1118–1124.

    PubMed  CAS  Google Scholar 

  52. Anderson KC, Skarin AT, Rosenthal DS, et al. Combination chemotherapy for advanced non-Hodgkin’s lymphomas other than diffuse histiocytic or undifferentiated histologies. Cancer Treat Rep 1984; 68:1343–1350.

    PubMed  CAS  Google Scholar 

  53. Coiffier B, Bryon PA, Berger F, et al. Intensive and sequential combination chemotherapy for aggressive malignant lymphoma (Protocol LNH-80). J Clin Oncol 1986; 4:147–153.

    PubMed  CAS  Google Scholar 

  54. Tura S, Mazza P, Gharlizoni F, et al. High-dose therapy followed by autologous bone marrow transplantation (ABMT) in previously untreated non-Hodgkin’s lymphoma. Scan J Hematol 1986; 37:347–352.

    CAS  Google Scholar 

  55. Takvorian T, Canellos GP, Ritz J, et al. Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin’s lymphoma with poor prognosis. N Engl J Med 1987; 316:1499–1505.

    Article  PubMed  CAS  Google Scholar 

  56. Baumgartner C, Delaleu B, Imbach P, et al. Autologous bone marrow transplantation for Burkitt’s lymphoma: Marrow purging with anti-y 29/55 monoclonal antibody and complement. IARC Sci Publ 1985; 60:435–440.

    PubMed  Google Scholar 

  57. Vaughan WP, Weisenburger DD, Sanger W, et al. Early leukemic recurrence of non-Hodgkin’s lymphoma after high dose antineoplastic therapy with autologous marrow rescue. Bone Marrow Transplant 1987; 1:373–378.

    PubMed  CAS  Google Scholar 

  58. Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin’s lymphomas. 1984; 311:1471–1475.

    CAS  Google Scholar 

  59. Rohtiner AZS, Barrett MJ, Arnott S, et al. Ablative therapy supported by autologous bone marrow transplantation (ABMT) with in vitro treatment of marrow in patients with B cell malignancy. Blood 1986; 68:241.

    Google Scholar 

  60. Philip T, Armitage JO, Cahn JV, et al. Pilot study of the DHAP rescue protocol and of a new conditioning regimen in responding NHL at relapse. Proc XIV EBMT 1988; 3:81.

    Google Scholar 

  61. Feinleib M, MacMahan B. Duration of survival in multiple myeloma. J Natl Cancer Inst 1960; 24:1259–1269.

    PubMed  CAS  Google Scholar 

  62. Alexanian R, Balcerzak S, Bonnet J, et al. Prognostic factors in multiple myeloma. Cancer 1975; 16:1192–1202.

    Article  Google Scholar 

  63. Hansen OP, Galton DAG. Classification and prognostic variable in myelomatosis. Scand J Hematol 1985; 35:10–19.

    Article  CAS  Google Scholar 

  64. Gobbi M, Cavo M, Savelli GA, et al. Prognostic factors and survival in multiple myeloma. Analysis of 91 cases treated by melphalan and prednisone. Hematologica 1980; 65:437–445.

    CAS  Google Scholar 

  65. Barlogi B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984; 310:1353–1356.

    Article  Google Scholar 

  66. Alexanian R, Barlogie B, Dixon D. High dose glucocorticoid treatment of resistant myeloma. Ann Intern Med 1984; 105:8–11.

    Google Scholar 

  67. Cavo M, Gobbi M, Tura S. Peptichemia in multiple myeloma. Hematologica 1981; 66:208–215.

    CAS  Google Scholar 

  68. McElwain TJ, Selby PJ, Perran TJ, et al. High dose melphalan of multiple myeloma. Int Soc Hematol 1986; 4:204.

    Google Scholar 

  69. McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma cell leukemia and myeloma. Lancet 1983; 2:822–824.

    Article  PubMed  CAS  Google Scholar 

  70. Barlogie B, Hall R, Zander H, et al. High dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 1986; 67:1298–1301.

    PubMed  CAS  Google Scholar 

  71. Bergsegel DR. Total body irradiation for myelomatosis. Br Med J 1971; 2:325–331.

    Article  Google Scholar 

  72. Kyle RA. Multiple myeloma: Review of 869 cases. Mayo Clin Proc 1975; 50:29–34.

    PubMed  CAS  Google Scholar 

  73. Osserman EF, Di Re LB, Pi Re J, et al. Identical twin marrow transplantation in multiple myeloma. Acta Hematol 1982; 68:215–223.

    Article  CAS  Google Scholar 

  74. Higby DJ, Brass C, Fitzpatrick J, et al. Bone marrow transplantation in multiple myeloma: A case report with protein studies. ASCO Abstract 1982; 192:C-747.

    Google Scholar 

  75. Tura S, Cavo M, Baccarani M, et al. Bone marrow transplantation in multiple myeloma. Scand J Hematol 1986; 36:176–179.

    Article  CAS  Google Scholar 

  76. Wolff SN, McCurley TL, Giannore L. High-dose chemoradiotherapy with syngeneic bone marrow transplantation for multiple myeloma: A case report and literature review. Am J Hematol 1987; 26:191–198.

    Article  PubMed  CAS  Google Scholar 

  77. Gallamini A, Buffa F, Bacigalages A. Allogeneic bone marrow transplantation in multiple myeloma. Acta Hematologica 1987; 77:111–114.

    Article  CAS  Google Scholar 

  78. Waldmann H, Polliack A, Hale G, et al. Elimination of graft-versus-host disease by in-vitro depletion of allo-reactive lymphocytes with monoclonal rat anti-human lymphocyte antibody (CAMPATH-1). Lancet 1984; 2:483–485.

    Article  PubMed  CAS  Google Scholar 

  79. Yehuda AB, Or R, Naparstek E, et al. T-cell depleted bone marrow transplantation for plasma cell myeloma. Blut 1988; 56:229–231.

    Article  PubMed  CAS  Google Scholar 

  80. Barlogie B, Alexanian R, Dicke KA. High-dose chemoradiotherapy with autologous bone marrow transplantation for resistant multiple myeloma. Blood 1987; 70:869–872.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Julie M. Vose
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James O. Armitage
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Philip J. Bierman
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. MD Anderson Cancer Center, Houston, Texas, USA

    Richard Champlin M.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1995 Kluwer Academic Publishers

About this chapter

Cite this chapter

Vose, J.M., Armitage, J.O., Bierman, P.J. (1995). Bone marrow transplantation for Hodgkin’s disease, non-Hodgkin’s lymphoma and multiple myeloma. In: Champlin, R. (eds) Bone Marrow Transplantation. Cancer Treatment and Research, vol 50. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1493-6_15

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-1493-6_15

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4612-8803-9

  • Online ISBN: 978-1-4613-1493-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation